101 related articles for article (PubMed ID: 8481017)
1. A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching.
Riccardi VM
Arch Dermatol; 1993 May; 129(5):577-81. PubMed ID: 8481017
[TBL] [Abstract][Full Text] [Related]
2. Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen.
Riccardi VM
Arch Dermatol; 1987 Aug; 123(8):1011-6. PubMed ID: 3115189
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
Abelson MB; Ferzola NJ; McWhirter CL; Crampton HJ
Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
6. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
7. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
8. [Effect of ketotifen in urticaria factitia and urticaria cholinergica in a crossover double-blind trial].
Cap JP; Schwanitz HJ; Czarnetzki BM
Hautarzt; 1985 Sep; 36(9):509-11. PubMed ID: 3905713
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference.
Leonardi A; Zafirakis P
Curr Med Res Opin; 2004 Aug; 20(8):1167-73. PubMed ID: 15324519
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
12. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of ketotifen in a controlled double-blind food challenge study in patients with food allergy.
Boner AL; Richelli C; Antolini I; Vibelli C; Andri L
Ann Allergy; 1986 Jul; 57(1):61-4. PubMed ID: 3524320
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ketotifen in the prophylactic treatment of bronchial asthma in children.
Naspitz CK; Freire CA
Allergol Immunopathol (Madr); 1988; 16(1):27-31. PubMed ID: 3381712
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pruritus with topically applied opiate receptor antagonist.
Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
[TBL] [Abstract][Full Text] [Related]
18. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
19. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
20. [Ketotifen fumarate (Zaditen) eye drops in the treatment of seasonal allergic conjunctivitis].
Haicl P; Cerná H
Cesk Slov Oftalmol; 2004 Sep; 60(5):362-7. PubMed ID: 15566225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
